🖼
Figure 5 — Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-40988129-5
Figure 5Figure 5
Associations between CSF biomarker levels and disability scores (EDSS) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) . Scatter plots showing CSF biomarker concentrations plotted against Expanded Disability Status Scale (EDSS) scores at the time of lumbar puncture in patients with MOGAD (blue points and regression lines) and NMOSD (orange points and regression lines). Solid lines represent linear regression fits with shaded areas denoting 95% confidence intervals. Biomarkers shown include neutrophil elastase (nEla), myeloperoxidase (MPO), matrix metalloproteinase-8 (MMP-8), neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), S100 calcium-binding protein B (S100B), complement factor C5 and complement activation product C5a. Biomarker concentrations ( y -axis) are presented in pg/ml, except for C5 (ng/ml
▸Metadata
| pmid | paper-40988129 |
| caption | Associations between CSF biomarker levels and disability scores (EDSS) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) . S |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC13058455/bin/awaf345f5.jpg |
| paper_title | Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. |
| figure_label | Figure 5 |
| figure_number | 5 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.